
Fulcrum Therapeutics, Inc.
USD3.22
+0.08 (+2.55%)
CEO
Alexander C. Sapir
IPO Date
2019-07-18
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$3.10
Prev. Close
$3.14
Day Low
$3.10
Day High
$3.27
52W Low
$2.83
52W High
$15.74
Market Cap
$0.17B
Volume
5.59M
Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the Potential Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)